New coronavirus infection SARS-CoV-2 in adult patients with inborn errors of immunity
- Authors: Roppelt A.A.1,2, Mаrkina U.A.1, Bobrikova E.N.1, Кruglova T.S.1, Мukhina O.A.1, Lebedkina M.S.1, Andrenova G.V.1, Chernov A.A.1, Alekseeva E.I.3,4, Karaulov A.V.3, Lysenko M.A.1,5, Fomina D.S.1,3,6
-
Affiliations:
- Moscow City Hospital 52
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- The First Sechenov Moscow State Medical University (Sechenov University)
- National Medical Research Center for Children's Health
- The Russian National Research Medical University named after N.I. Pirogov
- Astana Medical University
- Issue: Vol 21, No 2 (2024)
- Pages: 216-229
- Section: Original studies
- URL: https://journals.rcsi.science/raj/article/view/260057
- DOI: https://doi.org/10.36691/RJA16521
- ID: 260057
Cite item
Abstract
BACKGROUND: Diagnosis and treatment of COVID-19 in patients with primary immunodeficiency, or inborn errors of immunity, are often challenging.
AIM: Description of the COVID-19 course and therapy of adult patients with primary immunodeficiency treated in medical organizations of Moscow Healthcare Department.
MATERIALS AND METHODS: We analyzed a cohort of 68 patients over 18 years (median ― 35 years) with primary immunodeficiency; 91% of patients have primary immunodeficiency with predominantly antibody deficiencies. Altogether 90 cases of the new СOVID-19 were analyzed: in 68 cases infection occurred for the first time, in 22 cases it recurred. The duration of the disease ranged from 3 to 80 days. Duration of PCR-positivity ranged from 0 to 59 days, median 8 days.
RESULTS: Patients with Wuhan and Delta strains had more severe inflammatory signs according to C-reactive protein and lactate dehydrogenase, in patients with Wuhan lung involvement on CT-scam was larger. In demonstrated group of patients higher C-reactive protein correlated with larger lung involvement, longer duration of the disease and PCR-positivity, significant lymphopenia also correlated with higher C-reactive protein. To our data regularity of intravenous immunoglobulin therapy and IgG trough level didn’t correlate with infection severity and duration of the disease and virus-carriage.
Indirectly, the change in the spectrum of medicine used in patients of the analyzed group coincided with the virus strain evolution. Anti-inflammatory therapy was mainly presented by dexamethasone and antagonists to interleukin 6 or its receptor (anti-IL-6): 55% and 73% for Wuhan, 63% and 50% for Delta, 17% and 39% for Omicron. Then, preference was gradually given to the target anti-cytokine medicine. Etiotropic antiviral therapy was more often used to treat infection caused by Wuhan and Delta strains ― 32% and 38%, respectively (in 17% for Omicron). With shifting toward immunotherapy by specific against COVID-19 immunoglobulins and monoclonal antibody to SARS-CoV-2: 5% and 9% for Wuhan, 0% and 75% for Delta, 48% and 83% for Omicron, respectively. Immune and etiotropic therapy was not carried out in Wuhan in 39%, in Delta in 43%, in Omicron in 41% of cases. The overall mortality rate from COVID-19 in the analyzed group was 3%.
CONCLUSION: Patients with primary immunodeficiency represent a vulnerable group to the SARS-CoV-2 virus with a high risk of not only severe, but also a protracted and undulating course of infection, what must be taken into account for the correct interpretation of the patient's condition and the timely administration of the appropriate therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Anna A. Roppelt
Moscow City Hospital 52; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Author for correspondence.
Email: roppelt_anna@mail.ru
ORCID iD: 0000-0001-5132-1267
SPIN-code: 7249-4423
MD, Cand. Sci. (Med.)
Russian Federation, Moscow; MoscowUlyana A. Mаrkina
Moscow City Hospital 52
Email: itchermd@gmail.com
ORCID iD: 0000-0002-6646-4233
Russian Federation, Moscow
Elena N. Bobrikova
Moscow City Hospital 52
Email: elena.bobrikova.69@mail.ru
ORCID iD: 0000-0002-6534-5902
SPIN-code: 5806-7260
Russian Federation, Moscow
Tatiana S. Кruglova
Moscow City Hospital 52
Email: surckova.t@yandex.ru
ORCID iD: 0000-0002-4949-9178
SPIN-code: 2884-5000
Russian Federation, Moscow
Olga A. Мukhina
Moscow City Hospital 52
Email: mukhina.o.a@gmail.com
ORCID iD: 0000-0002-3794-4991
SPIN-code: 7721-1941
Russian Federation, Moscow
Marina S. Lebedkina
Moscow City Hospital 52
Email: marina.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
SPIN-code: 1857-8154
Russian Federation, Moscow
Gerelma V. Andrenova
Moscow City Hospital 52
Email: Andrenovagv@mail.ru
ORCID iD: 0000-0001-7053-3900
SPIN-code: 2891-1650
Russian Federation, Moscow
Anton A. Chernov
Moscow City Hospital 52
Email: sbornaya1med@yandex.ru
ORCID iD: 0000-0001-6209-387X
SPIN-code: 5893-5394
Russian Federation, Moscow
Ekaterina I. Alekseeva
The First Sechenov Moscow State Medical University (Sechenov University); National Medical Research Center for Children's Health
Email: alekatya@yandex.ru
ORCID iD: 0000-0002-3874-4721
SPIN-code: 4713-9943
MD, Dr. Sci. (Med.), Professor, corresponding member of the Russian Academy of Sciences
Russian Federation, Moscow; MoscowAlexander V. Karaulov
The First Sechenov Moscow State Medical University (Sechenov University)
Email: drkaraulov@mail.ru
ORCID iD: 0000-0002-1930-5424
SPIN-code: 4122-5565
MD, Dr. Sci. (Med.), Professor, academician of the Russian Academy of Sciences
Russian Federation, MoscowMariana A. Lysenko
Moscow City Hospital 52; The Russian National Research Medical University named after N.I. Pirogov
Email: gkb52@zdrav.mos.ru
ORCID iD: 0000-0001-6010-7975
SPIN-code: 3887-6250
MD, Dr. Sci. (Med.), Professor
Russian Federation, Moscow; MoscowDaria S. Fomina
Moscow City Hospital 52; The First Sechenov Moscow State Medical University (Sechenov University); Astana Medical University
Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, Moscow; Moscow; Astana, Republic of KazakhstanReferences
- Rahman S, Montero MT, Rowe K, et al. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: Review of current evidence. Expert Rev Clin Pharmacol. 2021;14(5):601–621. doi: 10.1080/17512433.2021.1902303
- Howard-Jones AR, Burgner DP, Crawford NW, et al. COVID-19 in children. II: Pathogenesis, disease spectrum and management. J Paediatr Child Health. 2022;58(1):46–53. EDN: DUDXBF doi: 10.1111/jpc.15811
- Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19). Temporary Methodological Recommendations of the Ministry of Health of the Russian Federation, version 17 of 14.12.2022. (In Russ).
- Delavari S, Abolhassani H, Abolnezhadian F, et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. J Clin Immunol. 2021;41(2):345–355. EDN: MPQBSG doi: 10.1007/s10875-020-00928-x
- Tangye SG, Al-Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–1507. EDN: TEUJVD doi: 10.1007/s10875-022-01289-3
- Aydiner KE, Eltan BS, Babayeva R, et al. Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses. Allergy. 2022;77(1):282–295. EDN: GSOQEO doi: 10.1111/all.15025
- Meyts I, Bucciol G, Quinti I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J Allergy Clin Immunol. 2021;147(2):520–531. EDN: LBOGVG doi: 10.1016/j.jaci.2020.09.010
- Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370(6515):eabd4570. EDN: VQUEYH doi: 10.1126/science.abd4570
- Zhang Q, Bastard P, Cobat A, et al. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603(7902):587–598. EDN: WGUBVJ doi: 10.1038/s41586-022-04447-0
- Kahn NY, Mukhina AA, Rodina SA, et al. COVID-19 infection in patients with primary immunodeficiencies. Pediatriya: Zhurnal imeni G.N. Speranskogo. 2020;99(6):83–90. EDN: PQNVZT doi: 10.24110/0031-403X-2020-99-6-83-90
- Tangye SG, Abel L, Al-Muhsen S, et al. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. J Allergy Clin Immunol. 2023;151(4):818–831. EDN: GRMEIO doi: 10.1016/j.jaci.2022.11.010
- Milota T, Sobotkova M, Smetanova J, et al. Risk factors for severe COVID-19 and hospital admission in patients with inborn errors of immunity: Results from a multicenter nationwide study. Front Immunol. 2022;(13):835770. EDN: EPALIY doi: 10.3389/fimmu.2022.835770
- Drzymalla E, Green RF, Knuth M, et al A. COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review. Clin Immunol. 2022;(243):109097. EDN: WYPSAY doi: 10.1016/j.clim.2022.109097
- ESID diagnostic criteria for PID [Electronic resource]. Available from: https://esid.org/layout/set/print/content/view/full/12919#Q7. Accessed: 15.02.2024.
- Shcherbina AY, Kuzmenko NB. Classification of primary immunodeficiencies as a reflection of modern ideas about their pathogenesis and therapeutic approaches. Rossiiskii zhurnal detskoi gematologii i onkologii. 2017;4(3):51–57. EDN: ZFDCKT doi: 10.17650/2311-1267-2017-4-3-51-57
- World Health Organization. International statistical classification of diseases and related health problems. 10th revision, Vol. 1, tabilar list. Fifth edition. 2016. P. 242–244.
- Schmidt A, Peters S, Knaus A, et al. TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. NPJ Genom Med. 2021;6(1):55. EDN: CFVLLS doi: 10.1038/s41525-021-00220-w
- Ito T, Kanzler H, Duramad O, et al. Specialization, kinetics, and repertoire of type I interferon responses by human plasmacytoid predendritic cells. Blood. 2006;107(6):2423–2431. doi: 10.1182/blood-2005-07-2709
- Bastard P, Lévy R, Gervais A, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218(7):e20210554. EDN: UNAMWT doi: 10.1084/jem.20210554
- Manry J, Bastard P, Gervais A, et al. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc Nat Acad Sci USA. 2022;119(21):e2200413119. EDN: ILOFNS doi: 10.1073/pnas.2200413119
- Shields AM, Anantharachagan A, Arumugakani G, et al. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clin Exp Immunol. 2022;209(3):247–258. EDN: GOZILL doi: 10.1093/cei/uxac008
- Kuster JK, Unlu S, Makin TA, et al. Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency. J Allergy Clin Immunol Pract. 2022;10(2):633–636.e3. EDN: XUDOBG doi: 10.1016/j.jaip.2021.11.030
- Young BE, Ong SW, Kalimuddin S, et al. Singapore 2019 Novel Coronavirus Outbreak Research Team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488–1494. doi: 10.1001/jama.2020.3204
- Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656–657. doi: 10.1016/ S1473-3099(20)30232-2
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;95(7):834–847 EDN: JKJBTU doi: 10.1002/ajh.25829
- Lang-Meli J, Fuchs J, Mathe P, et al. Case series: Convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency. J Clin Immunol. 2022;42(2):253–265. doi: 10.1007/s10875-021-01193-2
- Brown LK, Moran E, Goodman A, et al. Treatment of chronic or relapsing COVID-19 in immunodeficiency. J Allergy Clin Immunol. 2022;149(2):557–561.e1. doi: 10.1016/j.jaci.2021.10.031
- Durkee-Shock JR, Keller MD. Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity. Ann Allergy Asthma Immunol. 2022;129(5):562–571.e1. doi: 10.1016/j.anai.2022.06.009
- Roppelt AA, Lebedkina MS, Chernov AA, et al. Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies. Therapeut Arch. 2023;95(1):78–84. EDN: OZZWVC doi: 10.26442/00403660.2023.01.202088
- Alhumaid S, Al Mutair A, Alali J, et al. Efficacy and safety of tixagevimab/cilgavimab to prevent COVID-19 (pre-exposure prophylaxis): A systematic review and meta-analysis. Diseases (Basel, Switzerland). 2022;10(4):118. doi: 10.3390/diseases10040118
- Totschnig D, Augustin M, Niculescu I, et al. SARS-CoV-2 pre-exposure prophylaxis with sotrovimab and tixagevimab/cilgavimab in immunocompromised patients-A single-center experience. Viruses. 2022;14(10):2278. EDN: PILQSU doi: 10.3390/v14102278
- Calabrese C, Kirchner E, Villa-Forte A, et al. Early experience with tixagevimab. Cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity. RMD Open. 2022;8(2):e002557. EDN: XHCXEQ doi: 10.1136/rmdopen-2022-002557
- Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. Lancet. 2022;399(10332):1303–1312. doi: 10.1016/S0140-6736(22)00462-7